(Q45257716)

English

Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study

scientific article published in March 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

0 references

Josep Maria Haro

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

author name string

E T Edgell

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

D Novick

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

J Alonso

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

L Kennedy

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

M Ratcliffe

7

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

A Breier

8

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

SOHO advisory board

9

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

language of work or name

0 references

publication date

1 March 2005

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Acta Psychiatrica Scandinavica

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

111

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

220-231

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

Content and quality of 2000 controlled trials in schizophrenia over 50 years

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

Efficacy and safety of novel antipsychotics: a critical review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

A comparison of observational studies and randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

Randomized, controlled trials, observational studies, and the hierarchy of research designs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

Comments on "Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders" by Tran and Associates

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

Selection Bias in Clinical Trials With Antipsychotics

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2004.00450.X

21 January 2018

Identifiers

10.1111/J.1600-0447.2004.00450.X

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45257716&oldid=2071826818"